Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women With Recurrent Vulvovaginal Candidiasis: A Randomized Controlled Study

Conditions: Recurrent Vulvovaginal Candidiasis Interventions: Biological: Vaccine Sponsors: LimmaTech Biologics AG; GlaxoSmithKline Recruiting

Source: ClinicalTrials.gov - January 4, 2024 Category: Research Source Type: clinical trials